Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel (NCT07765446)
A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy
🩺 Plain-English Summary (8th-Grade Level)
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).
Who can join: Review the eligibility criteria below.
Location: Clinical Research Facility — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Clinical Research Facility — Baltimore, Maryland
- Clinical Research Facility — East Brunswick, New Jersey
📞 Contact the Study Coordinator
Phone: (617) 580-2520
Email: DL-2501-GLB-201-EligibilityReview@Sironax.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chemotherapy-induced Peripheral Neuropathy
- The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) — Boston, Massachusetts
- NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy — Iowa City, Iowa
- Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) — Toronto, Ontario
- Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) — Clermont, Florida
- Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy — Houston, Texas
- PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy — Middletown, Connecticut
Explore by condition: All Chemotherapy-induced Peripheral Neuropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.